Ads
related to: $35 asthma inhaler- Getting Started
Learn More About Dosing Schedules
Find Answers To Your Questions
- Register For A Webinar
Learn From Medical Professionals
Hear From Real Patients Like You
- Getting Started
Search results
Results From The WOW.Com Content Network
Following years of public outcry about the high cost of inhalers, the two drugmakers — along with a third, GlaxoSmithKline — have committed to capping the out-of-pocket cost at $35 a month.
Boehringer had also said it would cap out-of-pocket costs for its inhaler products for chronic lung disease and asthma to $35 per month, starting June 1. AstraZeneca to cap US out-of-pocket costs ...
(Reuters) - Boehringer Ingelheim will reduce out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma to $35 per month starting June 1, the German drugmaker ...
The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...
The Affordable Insulin Now Act is a bill in the United States Congress intended to cap out-of-pocket insulin prices under private health insurance and Medicare at no more than $35 per month. [ 1 ] The bill was first introduced on February 25, 2022, by Representative Angie Craig ( D - MN ). [ 2 ]
Philip Morris International Inc. (PMI) is an American multinational tobacco company, with products sold in over 180 countries. The most recognized and best selling product of the company is Marlboro; [4] its other major cigarette brands include L&M and Chesterfield. [5]
Ad
related to: $35 asthma inhaler